Multaq
Key product launches of 2011
December 19, 2011Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing 2011, Actos, Benlysta, Brilique, Eliquis, Eylea, Incivek, Jevtana, Multaq, Victrelis, Xalkori, Yervoy, Zytiga, avastin, gilenya, key products
Avastin 2011 saw a handful of high profile drugs suffer because of new safety and efficacy concerns. Chief among these …
Multaq raises risk of death in permanent AF patients
November 16, 2011Sales and Marketing AF, Multaq, Sanofi
More bad news for Sanofi’s Multaq as new data shows the drug doubles the risk of death in people with …
Safety concerns prompt Multaq restrictions
September 26, 2011Sales and Marketing Multaq
The European Medicines Agency has recommended Sanofi’s Multaq be restricted due to ongoing concerns about its safety profile. The drug …
Sanofi’s Multaq in the dock
September 7, 2011Sales and Marketing Multaq, Sanofi
The EMA will later this month decide whether Sanofi’s Multaq can remain on the market after reports emerged of serious …
EMA widens safety review of Sanofi’s Multaq
July 12, 2011Sales and Marketing Multaq, Sanofi
European regulators are to extend their assessment of the risks associated with Sanofi’s atrial fibrillation (AF) medicine Multaq to take …
Bayer contraceptive advert breaches Code of Practice
May 27, 2011Medical Communications ABPI Code of Practice, Bayer, Multaq, Sanofi, Yasmin
Bayer Healthcare has been singled out for “particular censure” by the PMCPA, the body which regulates the ABPI Code of …
Companies join forces to promote AF awareness
February 16, 2011Medical Communications, Sales and Marketing AF, Multaq, Pradaxa, apixaban, atrial fibrillation
Boehringer Ingelheim and Sanofi-Aventis are to co-sponsor the World Heart Federation’s global atrial fibrillation (AF) education campaign. AF AWARE was …
Generics force Sanofi into standstill
February 9, 2011Sales and Marketing 2010 pharma results, Jevtana, Multaq, Sanofi, Sanofi-Aventis, generics
An onslaught of generic competition combined with healthcare cuts in the US and Europe meant Sanofi-Aventis’ revenues were brought to …
FDA issues Multaq liver warning
January 17, 2011Sales and Marketing FDA, Multaq, atrial fibrilation, dronedarone
US regulators have warned doctors and patients about the risk of severe liver injury associated with Sanofi-Aventis’ atrial fibrillation (AF) …
Sanofi’s Multaq in pole position for AF market
September 6, 2010Sales and Marketing Multaq, Sanofi-Aventis, atrial fibrilation
New European Society of Cardiology guidelines on treating atrial fibrillation (AF) include a recommendation for Sanofi-Aventis’ Multaq. The endorsement is …
Multaq given limited approval from NICE
August 25, 2010Medical Communications, Sales and Marketing Multaq, NICE, Sanofi-Aventis, atrial, dronedarone
NICE has given a restricted approval to Sanofi-Aventis’s Multaq as a second line treatment for atrial fibrillation patients. The guidance …
NICE reaffirms positive opinion on Multaq
July 19, 2010Sales and Marketing Multaq, NICE, antiarrhythmic, dronedarone
In its final draft guidance, UK cost-effectiveness body NICE has reaffirmed its previous positive opinion to recommend the limited use …
Novel anticoagulants set to lead atrial fibrillation market
July 9, 2010Sales and Marketing Brinavess, Multaq, Pradaxa, Xarelto, apixaban, atrial fibrilation
Novel anticoagulants set to capture the atrial fibrillation market by 2019, according to a new report. Analysts Decision Resources say …
NICE changes its mind on Multaq
March 30, 2010Sales and Marketing Multaq, NICE, Sanofi-Aventis
NICE has given preliminary approval of Sanofi-Aventis’ Multaq for the management of patients with atrial fibrillation. The decision reverses an …
NICE says no to Multaq
January 8, 2010Sales and Marketing Multaq, NICE, Sanofi
NICE has rejected Sanofi-Aventis’ new anti-blood clot treatment Multaq (dronedarone) for use on the NHS because of its cost. According …
Latest content
FibroFind appoints Lee Borthwick as CEO
